TP53 and neoplasm: The MDM2 gene, a cellular protooncogene that is amplified in more than 7% of all human cancer cases [3], interacts with p53 and counteracts the tumor-suppressive function of p53 protein through various mechanisms, including blocking its transcriptional activity, exporting it into the cytoplasm and most importantly promoting its degradation [4].